SIGMAR1 and breast carcinoma: Furthermore, the versatility of the agonists and antagonists that influence SigmaR1 activity (Table 1) suggests a complex role for this receptor and requires further mechanistic analyses of its function in order to facilitate clinical utility in the personalized management of heterogenous diseases such as breast cancer.